Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

被引：3

作者：

Trevisan, B. ^{[1
]}

Pepe, F. F. ^{[1
]}

Vallini, I. ^{[2
]}

Montagna, E. ^{[3
]}

Amoroso, D. ^{[4
]}

Berardi, R. ^{[5
]}

Butera, A. ^{[6
]}

Cagossi, K. ^{[7
]}

Cavanna, L. ^{[8
]}

Ciccarese, M. ^{[9
]}

Cinieri, S. ^{[10
]}

Cretella, E. ^{[11
]}

De Conciliis, E. ^{[12
]}

Febbraro, A. ^{[13
]}

Ferrau, F. ^{[14
]}

Ferzi, A. ^{[15
]}

Baldelli, A. ^{[16
]}

Fontana, A. ^{[17
]}

Gambaro, A. R. ^{[18
]}

Garrone, O. ^{[19
]}

Gebbia, V. ^{[20
]}

Generali, D. ^{[21
]}

Gianni, L. ^{[22
]}

Giovanardi, F. ^{[23
]}

Grassadonia, A. ^{[24
]}

Leonardi, V. ^{[25
]}

Sarti, S. ^{[26
]}

Musolino, A. ^{[27
]}

Nicolini, M. ^{[22
]}

Putzu, C. ^{[28
]}

Riccardi, F. ^{[29
]}

Santini, D. ^{[30
]}

Sarobba, M. G. ^{[31
]}

Schintu, M. G. ^{[32
]}

Scognamiglio, G. ^{[33
]}

Spadaro, P. ^{[34
]}

Taverniti, C. ^{[35
]}

Toniolo, D. ^{[36
]}

Tralongo, P. ^{[37
]}

Turletti, A. ^{[38
]}

Valenza, R. ^{[39
]}

Valerio, M. R. ^{[40
]}

Vici, P. ^{[41
]}

Clivio, L. ^{[42
]}

Torri, V. ^{[42
]}

Cazzaniga, M. E. ^{[1
]}

机构：

[1] Azienda Osped San Gerardo, Monza, Italy

[2] Osped Circolo & Fdn Macchi, Varese, Italy

[3] European Inst Oncol, Milan, Italy

[4] Osped Versilia, Camaiore, Italy

[5] Azienda Osped Univ Osped Riuniti, Torrette, Italy

[6] Nuovo Osped San Giovanni Dio, Florence, Italy

[7] Osped Ramazzini, Carpi, Italy

[8] Azienda Osped Piacenza, Piacenza, Italy

[9] Osped Vito Fazzi, Lecce, Italy

[10] Osped A Perrino, Brindisi, Italy

[11] Osped Bolzano, Bolzano, Italy

[12] ASL Asti, Asti, Italy

[13] Osped S Cuore Gesu Fatebenefratelli, Benevento, Italy

[14] Osped San Vincenzo, Taormina, Italy

[15] Azienda Osped Osped Civile Legnano, Magenta, Italy

[16] Osped San Salvatore, Coppito, Italy

[17] Azienda Osped Univ Pisana, Pisa, Italy

[18] ASST Fatebenefratelli Sacco, Milan, Italy

[19] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[20] Osped La Maddalena, Palermo, Italy

[21] Ist Ospitalieri Cremona, Cremona, Italy

[22] Osped Infermi, Rimini, Italy

[23] AUSL Romagna, Emilia Romagna, Italy

[24] Osped SS Annunziata, Taranto, Italy

[25] Osped Civ, Palermo, Italy

[26] IRCCS Ist Sci Romagnolo Studio Cura Tumori, Meldola, Italy

[27] Osped Parma, Parma, Italy

[28] Azienda Osped Univ, Sassari, Italy

[29] Osped Antonio Cardarelli, Naples, Italy

[30] Univ Campus Biomed, Rome, Italy

[31] Osped San Francesco, Nuoro, Italy

[32] Osped Giovanni Paolo II, Lecce, Italy

[33] Osped Valduce, Como, Italy

[34] Casa Cura Villa Salus Messina, Messina, Italy

[35] Osped Molinette, Turin, Italy

[36] Osped Circolo, Rho, Italy

[37] Osped Umberto I, Rome, Italy

[38] Osped Martini, Turin, Italy

[39] PO Vittorio Emanuele, Gela, Italy

[40] AOU Policlin Paolo Giaccone, Palermo, Italy

[41] INT Regina Elena, Rome, Italy

[42] IRCCS Mario Negri Inst Pharmacol Res, Milan, Italy

来源：

SCIENTIFIC REPORTS | 2023年 / 13卷 / 01期

关键词：

PHASE-II TRIAL; 1ST-LINE TREATMENT; INTERNATIONAL SOCIETY; ORAL VINORELBINE; CAPECITABINE; MANAGEMENT; RECOMMENDATIONS; ANGIOGENESIS; PACLITAXEL; WOMEN;

D O I：

10.1038/s41598-023-39386-x

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT's activity in a real-life setting of elderly MBC patients. Data of patients & GE; 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75-98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3-4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.

引用

页数：9

共 50 条

[31] Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study
Hubbert, Laila
Mallios, Panagiotis
Karlstrom, Patric
Papakonstantinou, Andri
Bergh, Jonas
Hedayati, Elham
FRONTIERS IN ONCOLOGY, 2023, 13
[32] Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study
Lasagna, Angioletta
Albi, Giuseppe
Maserati, Renato
Zuccarini, Andrea
Quaccini, Mattia
Baldanti, Fausto
Sacchi, Paolo
Bruno, Raffaele
Pedrazzoli, Paolo
FRONTIERS IN ONCOLOGY, 2023, 13
[33] The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients - the final analysis of the Polish real-life survey PONDx
Jarzab, Michal
Litwiniuk, Maria
Innis, Paige
Lacko, Aleksandra
Enderle, Gesine
Czartoryska-Arlukowicz, Bogumila
Talerczyk, Malgorzata
Streb, Joanna
Wysocki, Piotr
Suchodolska, Grazyna
Szymanowski, Bartosz
Duchnowska, Renata
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2024, 28 (03): : 245 - 252
[34] The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancer
Quinten, Chantal
Kenis, C.
Hamaker, M.
Coolbrandt, A.
Brouwers, B.
Dal Lago, L.
Neven, P.
Vuylsteke, P.
Debrock, G.
Van den Bulck, H.
Smeets, A.
Schoffski, P.
Bottomley, A.
Wedding, U.
Wildiers, H.
JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (02) : 152 - 162
[35] Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS)
Decoster, Lore
Kenis, Cindy
Naessens, Benedicte
Houbier, Ghislain
De Man, Marc
Lambrecht, Guy
Monsaert, Els
Moons, Veerle
Vergauwe, Philippe
Preneni, Hans
Van Cutsem, Eric
Wildiers, Hans
JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (02) : 93 - 101
[36] Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results
Hofheinz, Ralf
Petersen, Volker
Kindler, Manfred
Schulze, Mathias
Seraphin, Joerg
Hoeffkes, Heinz-Gert
Valdix, Anette-R
Schroeder, Jan
Herrenberger, Julia
Stein, Alexander
Hinke, Axel
Arnold, Dirk
BMC CANCER, 2014, 14
[37] Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel
Marschner, Norbert
Salat, Christoph
Soeling, Ulrike
Hansen, Richard
Grebhardt, Sina
Harde, Johanna
Nusch, Arnd
Potthoff, Karin
CLINICAL BREAST CANCER, 2018, 18 (06) : E1323 - E1337
[38] Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice
Curtit, Elsa
Vannetzel, Jean-Michel
Darmon, Jean-Claude
Roche, Sophie
Bourgeois, Hugues
Dewas, Sylvain
Catala, Stephanie
Mereb, Emile
Fanget, Charlotte Furtos
Genet, Dominique
Forest, Anne-Marie
Bernier, Celine
Pivot, Xavier
BREAST, 2019, 44 : 39 - 45
[39] Results of darbepoetin alfa treatment of anaemia in chemotherapy-receiving breast cancer patients: a single-centre retrospective observational study
Jagiello-Gruszfeld, Agnieszka
Niwinska, Anna
Michalski, Wojciech
Pogoda, Katarzyna
Dubianski, Roman
Kunkiel, Michal
Lemanska, Izabela
Sienkiewicz, Renata
Gorniak, Anna
Kosakowska, Ewa
Nowecki, Zbigniew
ONCOLOGY IN CLINICAL PRACTICE, 2021, 17 (06): : 237 - 243
[40] Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort
Collet, Laetitia
Eberst, Lauriane
Ludovic, Gauthier
Debled, Marc
Hrab, Loana
Mouret-Reynier, Marie-Ange
Desmoulins, Isabelle
Goncalves, Anthony
Campone, Mario
Ferrero, Jean-Marc
Brain, Etienne
Uwer, Lionel
Eymard, Jean-Christophe
Dieras, Veronique
Simon, Gaetane
Leheurteur, Marianne
Dalenc, Florence
Vanlemmens, Laurence
Darlix, Amelie
Arnedos, Monica
Bachelot, Thomas
BREAST CANCER, 2023, 30 (02) : 329 - 341

← 1 2 3 4 5 →